The Registry Study of Takayasu Arteritis in East China

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Takayasu ArteritisMechanisms, DefensePregnancy RelatedTreatment RefusalOutcome
Interventions
BIOLOGICAL

Tocilizumab

The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.

DRUG

Leflunomide

The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.

Trial Locations (1)

200032

RECRUITING

Department of Rheumatology in Zhongshan hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER